Yung-Hung Luo
Overview
Explore the profile of Yung-Hung Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Liao B, Subramaniam S, Chiu C, Mersiades A, Ho C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100771.
PMID: 39877028
Introduction: -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed...
2.
Sun R, Liao P, Liao Y, Yeh Y, Chiang C, Chen Y, et al.
J Chin Med Assoc
. 2025 Jan;
PMID: 39865515
Background: Limited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment...
3.
Peng Y, Li D, Wampfler J, Luo Y, Kumar A, Gu Z, et al.
Oncol Rep
. 2024 Dec;
53(2.
PMID: 39704259
Targeted drugs have revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, the understanding of how cardiac comorbidity and toxicity affect the clinical outcomes of patients following targeted...
4.
Luo Y, Shen C, Chiang C, Chen Y
Ther Adv Med Oncol
. 2024 Oct;
16:17588359241284946.
PMID: 39391353
Background: Programmed cell death protein 1 ligand 1 (PD-L1) expression alone may not be the optimal predictor of immunotherapy (IO) efficacy in advanced non-small cell lung cancer (NSCLC). Evaluation of...
5.
Liao B, Chiang N, Chang G, Su W, Luo Y, Chong I, et al.
JCO Glob Oncol
. 2024 Sep;
10:e2400125.
PMID: 39348626
Purpose: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS...
6.
Lu C, Chen C, Chiu T, Chen C, Wei K, Lin S, et al.
J Formos Med Assoc
. 2024 Aug;
PMID: 39174397
The 2023 consensus from the Taiwanese Dermatological Association (TDA) and Taiwan Lung Cancer Society (TLCS) addresses the management of tyrosine kinase inhibitor (TKI)-induced skin toxicities in non-small cell lung cancer...
7.
Laah A, Tsai P, Yarmishyn A, Ching L, Chen C, Chien Y, et al.
Adv Sci (Weinh)
. 2024 Aug;
11(38):e2400370.
PMID: 39113226
NK2 Homeobox 1 (NKX2-1) is a well-characterized pathological marker that delineates lung adenocarcinoma (LUAD) progression. The advancement of LUAD is influenced by the immune tumor microenvironment through paracrine signaling. However,...
8.
Luo Y, Shen C, Chiang C, Huang H, Chen Y
Front Immunol
. 2024 Feb;
15:1269253.
PMID: 38343550
Background: Pulmonary infections are a crucial health concern for patients with advanced non-small-cell lung cancer (NSCLC). Whether the clinical outcome of pulmonary infection is influenced by immunotherapy(IO) remains unclear. By...
9.
Chiang C, Huang H, Luo Y, Shen C, Chao H, Tseng Y, et al.
Lung Cancer
. 2024 Jan;
188:107473.
PMID: 38232600
Objectives: Molecular subtyping of small cell lung cancer (SCLC) tumors based on the expression of four transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) using immunohistochemical (IHC) staining has recently emerged...
10.
Wang S, Xiong Y, Zhang Y, Wang H, Chen M, Li J, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38212124
Background: Immunotherapies targeting immune checkpoints have gained increasing attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular RNAs (circRNAs) have emerged as critical regulators of tumor immunity, particularly...